Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.2
3.0
Journals
JCM
Special Issues
Clinical Highlights in Uveal Melanoma
jcm-logo
Submit to Special Issue Submit Abstract to Special Issue Review for JCM Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Clinical Highlights in Uveal Melanoma

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Ophthalmology".

Deadline for manuscript submissions: 25 November 2025 | Viewed by 90

Special Issue Editors

Dr. Tomasz Chorągiewicz

E-Mail Website
Guest Editor
Department of General Ophthalmology, Medical University of Lublin, Lublin, Poland
Interests: corneal; ocular trauma
Dr. Joanna Dolar-Szczasny

E-Mail Website
Guest Editor
Department of General and Pediatric Ophthalmology, Medical University of Lublin, 20-093 Lublin, Poland
Interests: eye diseases; cataract
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The progress made regarding uveal melanoma therapy in recent years is noticeable. The availability of and advances made in the development of diagnostic and visualization devices has improved diagnostics. New strategies and improvements in radiotherapy and surgery techniques have enhanced treatment outcomes. The application of artificial intelligence offers hope for the better recognition of the disease and its prognosis. Clinical and laboratory observations along with basic science experiments help us to better understand the nature of the disease; however, uveal melanoma is still the most common primary intraocular tumor in adults, constituting a cause of visual impairment, blindness and even death. In this Special Issue, we welcome authors to submit papers on the clinical highlights in uveal melanoma, which will ensure that knowledge of this serious and challenging condition is up to date.

Dr. Tomasz Chorągiewicz
Dr. Joanna Dolar-Szczasny
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • choroidal melanoma
  • uveal melanoma
  • radiotherapy
  • enucleation
  • brachytherapy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Other

13 pages, 480 KiB  
Brief Report
A Brief Overview of Uveal Melanoma Treatment Methods with a Focus on the Latest Advances
by Krystian Wdowiak, Joanna Dolar-Szczasny, Robert Rejdak, Agnieszka Drab and Agnieszka Maciocha
J. Clin. Med. 2025, 14(12), 4058; https://doi.org/10.3390/jcm14124058 (registering DOI) - 8 Jun 2025
Abstract
Background: Uveal melanoma (UM) is a relatively rare malignancy, yet it remains the most common primary intraocular cancer in adults. Several risk factors have been identified, including light iris color, fair skin tone, and cutaneous freckles. Methods: The aim of this article was [...] Read more.
Background: Uveal melanoma (UM) is a relatively rare malignancy, yet it remains the most common primary intraocular cancer in adults. Several risk factors have been identified, including light iris color, fair skin tone, and cutaneous freckles. Methods: The aim of this article was an overview of the treatment methods for uveal melanoma, with a particular focus on emerging therapies such as tebentafusp and da-rovasertib. The research method was a review of the latest literature. Results: Genetic studies have uncovered key mutations in GNAQ and GNA11, which significantly contribute to UM pathogenesis. Treatment selection depends on tumor location and disease stage. In localized disease, radiotherapy—especially brachytherapy—is commonly used and generally effective. However, the prognosis worsens significantly once distant metastases, most often to the liver, develop, as no standard systemic therapy has demonstrated high efficacy in this setting. Recent years have seen the emergence of promising therapies, including tebentafusp, which stimulates immune responses against gp100-expressing melanoma cells, and darovasertib, a potent PKC inhibitor that targets MAPK pathway activation driven by GNAQ/GNA11 mutations. Both agents have shown encouraging tolerability; tebentafusp has demonstrated clinical benefit in Phase II and III trials, while darovasertib is still under investigation. Additionally, melphalan-based liver-directed therapy, particularly via hepatic arterial infusion (approved by the FDA), has shown potential in controlling liver-dominant disease in metastatic UM. This localized approach may provide significant benefit for patients with limited extrahepatic spread. Conclusions: Future research should focus on optimizing these novel strategies—tebentafusp, darovasertib, melphalan, and combination therapies—and on expanding our understanding of UM’s molecular drivers to enable the development of more effective, personalized treatments. Full article
(This article belongs to the Special Issue Clinical Highlights in Uveal Melanoma)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop